Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 15/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733432 | 0.78 | GPR84 (0.58) | MAPTPKMMEN1KMT2A | |
| SCHEMBL18255671 | 0.71 | PDE2A (0.74) | PDE2A | |
| SCHEMBL18247915 | 0.70 | PDE2A (0.55) | PDE2A | |
| SCHEMBL1908212 | 0.69 | MEN1 (0.66) | MAPTPKMMEN1KMT2A | |
| SCHEMBL803563 | 0.67 | PKM (0.54) | MAPTPKM | |
| SCHEMBL17422233 | 0.66 | POLB (0.50) | MAPTPKMMEN1KMT2A | |
| SCHEMBL18931726 | 0.65 | PKM (0.53) | MAPTPKMMEN1KMT2A | |
| SCHEMBL5552693 | 0.65 | SCN9A (0.55) | PKMMEN1KMT2A | |
| SCHEMBL15457569 | 0.65 | PKM (0.53) | MAPTPKMMEN1KMT2A | |
| SCHEMBL22050889 | 0.65 | MAPT (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635975-B | DGAT2 inhibitors | 伊莱利利公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | MAPT 2739/4885PDE2A 1320/4885PKM 2726/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | MAPT 2856/4885PDE2A 1352/4885PKM 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.